Home Nav
Nextech Invest Logo

Global Oncology Investment Expertise

We are a global investment advisor with a focus on oncology. Nextech is run by an experienced team of experts and supported by key opinion leaders in oncology.

We deploy our expertise to invest equity in companies developing cancer therapeutics.

Executive Management
Scientific Advisory Board
Executive Management
Executive Management

Portfolio Companies

Game Changing Cancer Companies

  • Agensys

    Acquired

    Fully human antibody drug conjugates for pancreatic cancer

  • A2 Biotherapeutics

    R&D

    Advanced targeting technology platform to improve natural immune defenses

  • Arrakis Therapeutics

    R&D

    Development of RNA-targeted small molecules (rSMs) to target undruggable proteins

  • Arvinas

    IPO

    First-in-class protein degradation therapeutics - PROTAC® - for cancer

  • Autolus

    IPO

    Autolus is a leader in cutting-edge T-cell therapies

  • Black Diamond Therapeutics

    Preclinical

    Targeting Genetically-Defined Allosteric Mutant Oncogenes

  • Blueprint Medicines

    IPO

    Highly selective kinase inhibitors for genomically defined cancer subsets

  • Cleave Biosciences

    Clinical Phase I

    Small molecule inhibitors targeting protein homeostasis

  • Ganymed Pharmaceuticals

    Acquired

    Ideal monoclonal antibodies for cancer treatment

  • IDEAYA Biosciences

    IPO

    Personalized synthetic lethality and immuno-oncology medicines

  • ImaginAb

    Clinical Phase II

    Antibody fragments for imaging of cancer

  • Jounce Therapeutics

    IPO

    Immunotherapeutics to create highly durable cancer treatments

  • Kronos Bio

    R&D

    Development of novel modulators of historically undruggable oncology targets

  • Kura Oncology

    IPO

    Small molecules that target cancer signaling pathways

  • MacroGenics

    Full Exit

    Antibodies for cancer immunotherapy

  • MolecularMD

    Acquired

    Cancer genotyping for targeted cancer therapies

  • Neon Therapeutics

    IPO

    Neoantigen based cancer vaccines

  • Palyon Medical

    Full Exit

    Implantable drug pumps for palliative care and diabetes

  • Peloton Therapeutics

    Acquired

    Small-molecule programs with a distinct target and mechanism of action

  • Revolution Medicines

    Clinical Phase I

    New medicines for patients against frontier oncology targets

  • Sunesis Pharmaceuticals

    Full Exit

    Small molecules for acute myeloid leukemia

  • TeLoRmedix

    Full Exit

    Targeted immunity in cancer and other diseases

  • TetraLogic Pharmaceuticals

    Full Exit

    Small molecule Smac mimetics for treatment of cancers

  • Tracon Pharmaceuticals

    IPO

    Antibodies targeting endoglin in cancer angiogenesis

  • Turning Point Therapeutics

    IPO

    Highly selective kinase inhibitors for secondary resistant mutations

  • Vividion Therapeutics

    R&D

    Cutting-edge platform to reveal druggable opportunities across the entire proteome

  • 24.07.2019

    Kura Oncology’s Menin-MLL Inhibitor KO-539 Receives...

  • 18.07.2019

    Blueprint Medicines Announces European Medicines Agency...

  • 15.07.2019

    Neon Therapeutics ’ Personal Neoantigen Vaccine Study...

Corporate Presentation

Get it now.

Portfolio Companies

Game Changing Cancer Companies

  • Agensys

    Acquired

    Fully human antibody drug conjugates for pancreatic cancer

  • A2 Biotherapeutics

    R&D

    Advanced targeting technology platform to improve natural immune defenses

  • Arrakis Therapeutics

    R&D

    Development of RNA-targeted small molecules (rSMs) to target undruggable proteins

  • Arvinas

    IPO

    First-in-class protein degradation therapeutics - PROTAC® - for cancer

  • Autolus

    IPO

    Autolus is a leader in cutting-edge T-cell therapies

  • Black Diamond Therapeutics

    Preclinical

    Targeting Genetically-Defined Allosteric Mutant Oncogenes

  • Blueprint Medicines

    IPO

    Highly selective kinase inhibitors for genomically defined cancer subsets

  • Cleave Biosciences

    Clinical Phase I

    Small molecule inhibitors targeting protein homeostasis

  • Ganymed Pharmaceuticals

    Acquired

    Ideal monoclonal antibodies for cancer treatment

  • IDEAYA Biosciences

    IPO

    Personalized synthetic lethality and immuno-oncology medicines

  • ImaginAb

    Clinical Phase II

    Antibody fragments for imaging of cancer

  • Jounce Therapeutics

    IPO

    Immunotherapeutics to create highly durable cancer treatments

  • Kronos Bio

    R&D

    Development of novel modulators of historically undruggable oncology targets

  • Kura Oncology

    IPO

    Small molecules that target cancer signaling pathways

  • MacroGenics

    Full Exit

    Antibodies for cancer immunotherapy

  • MolecularMD

    Acquired

    Cancer genotyping for targeted cancer therapies

  • Neon Therapeutics

    IPO

    Neoantigen based cancer vaccines

  • Palyon Medical

    Full Exit

    Implantable drug pumps for palliative care and diabetes

  • Peloton Therapeutics

    Acquired

    Small-molecule programs with a distinct target and mechanism of action

  • Revolution Medicines

    Clinical Phase I

    New medicines for patients against frontier oncology targets

  • Sunesis Pharmaceuticals

    Full Exit

    Small molecules for acute myeloid leukemia

  • TeLoRmedix

    Full Exit

    Targeted immunity in cancer and other diseases

  • TetraLogic Pharmaceuticals

    Full Exit

    Small molecule Smac mimetics for treatment of cancers

  • Tracon Pharmaceuticals

    IPO

    Antibodies targeting endoglin in cancer angiogenesis

  • Turning Point Therapeutics

    IPO

    Highly selective kinase inhibitors for secondary resistant mutations

  • Vividion Therapeutics

    R&D

    Cutting-edge platform to reveal druggable opportunities across the entire proteome

  • Agensys

    Acquired

    Fully human antibody drug conjugates for pancreatic cancer

  • A2 Biotherapeutics

    R&D

    Advanced targeting technology platform to improve natural immune defenses

  • Arrakis Therapeutics

    R&D

    Development of RNA-targeted small molecules (rSMs) to target undruggable proteins

  • Arvinas

    IPO

    First-in-class protein degradation therapeutics - PROTAC® - for cancer

  • Autolus

    IPO

    Autolus is a leader in cutting-edge T-cell therapies

  • Black Diamond Therapeutics

    Preclinical

    Targeting Genetically-Defined Allosteric Mutant Oncogenes

  • Blueprint Medicines

    IPO

    Highly selective kinase inhibitors for genomically defined cancer subsets

  • Cleave Biosciences

    Clinical Phase I

    Small molecule inhibitors targeting protein homeostasis

  • Ganymed Pharmaceuticals

    Acquired

    Ideal monoclonal antibodies for cancer treatment

  • IDEAYA Biosciences

    IPO

    Personalized synthetic lethality and immuno-oncology medicines

  • ImaginAb

    Clinical Phase II

    Antibody fragments for imaging of cancer

  • Jounce Therapeutics

    IPO

    Immunotherapeutics to create highly durable cancer treatments

  • Kronos Bio

    R&D

    Development of novel modulators of historically undruggable oncology targets

  • Kura Oncology

    IPO

    Small molecules that target cancer signaling pathways

  • MacroGenics

    Full Exit

    Antibodies for cancer immunotherapy

  • MolecularMD

    Acquired

    Cancer genotyping for targeted cancer therapies

  • Neon Therapeutics

    IPO

    Neoantigen based cancer vaccines

  • Palyon Medical

    Full Exit

    Implantable drug pumps for palliative care and diabetes

  • Peloton Therapeutics

    Acquired

    Small-molecule programs with a distinct target and mechanism of action

  • Revolution Medicines

    Clinical Phase I

    New medicines for patients against frontier oncology targets

  • Sunesis Pharmaceuticals

    Full Exit

    Small molecules for acute myeloid leukemia

  • TeLoRmedix

    Full Exit

    Targeted immunity in cancer and other diseases

  • TetraLogic Pharmaceuticals

    Full Exit

    Small molecule Smac mimetics for treatment of cancers

  • Tracon Pharmaceuticals

    IPO

    Antibodies targeting endoglin in cancer angiogenesis

  • Turning Point Therapeutics

    IPO

    Highly selective kinase inhibitors for secondary resistant mutations

  • Vividion Therapeutics

    R&D

    Cutting-edge platform to reveal druggable opportunities across the entire proteome

Executive Management
Scientific Advisory Board
Close

Newsletter Registration

Please fill in the subscription form completely. If you wish to modify your personal data or to change/cancel your newsletter subscription, this is possible at any time.

A link to your subscription profile can be found in every newsletter email.

Preview

* Compulsory fields

Close

Newsletter Registration

Your eMail have been successfully registered.

Close

This website uses cookies to provide you with the best possible service. By using our website, you consent to the use of cookies in accordance with our privacy policy. Here you can find out more.